Skip to Main content Skip to Navigation
Journal articles

Among CMV-positive renal transplant patients receiving non-T-cell depleting induction, the absence of CMV disease prevention is a safe strategy: a retrospective cohort of 372 patients

Abstract : Cytomegalovirus (CMV) is the most common opportunistic pathogen affecting renal transplant recipients, especially in the first months. CMV-seropositive renal transplant recipients (CMV R+) are at intermediate risk for CMV disease, but this risk is enhanced among CMV R+ receiving T-cell depleting induction, compared to CMV R+ receiving non-depleting induction. In this second group, data in favour of prophylactic antiviral treatment with valganciclovir to reduce CMV disease is sparse. In this retrospective and multicentric trial, we included 372 CMV R+ transplanted between January 2012 and April 2015 and receiving non-depleting induction. During the first year following transplantation, CMV disease occurred in 5/222 patients (2.25%) in the prophylaxis group and 9/150 (6%) in the no-prophylaxis group (difference + 3.7; 95%CI - 0.5 to 8; p=0.002 for non-inferiority). The incidence of allograft rejection and other infectious diseases was similar between the 2 groups. Graft and patient survival were similar at the end of follow-up. In conclusion, the absence of prophylaxis did not appear to have a deleterious effect for CMV diseases among CMV R+ receiving non-depleting induction.
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03095269
Contributor : Xavier Chard-Hutchinson <>
Submitted on : Tuesday, January 12, 2021 - 2:39:17 PM
Last modification on : Thursday, January 14, 2021 - 11:30:02 AM
Long-term archiving on: : Tuesday, April 13, 2021 - 6:40:05 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-06-03

Please log in to resquest access to the document

Identifiers

Citation

Hugoline Boulay, Emmanuel Oger, Diego Cantarovich, Philippe Gatault, Antoine Thierry, et al.. Among CMV-positive renal transplant patients receiving non-T-cell depleting induction, the absence of CMV disease prevention is a safe strategy: a retrospective cohort of 372 patients. Transplant Infectious Disease, Wiley, 2020, pp.e13541. ⟨10.1111/tid.13541⟩. ⟨hal-03095269⟩

Share

Metrics

Record views

43